Amgen (AMGN) Tops Q2 EPS by 76c, Offers Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $6.02, $0.76 better than the analyst estimate of $5.26. Revenue for the quarter came in at $9.18 billion versus the consensus estimate of $8.92 billion.

GUIDANCE:

Amgen sees FY2025 EPS of $20.20-$21.30, versus the consensus of $20.90. Amgen sees FY2025 revenue of $35-36 billion, versus the consensus of $35.36 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Citi upgrades Bath & Body Works to Buy with $25 price target
• BofA Securities Reiterates Buy Rating on NVIDIA (NVDA)